Introduction
Patients with acute myeloid leukemia (AML) and hyperleukocytosis, defined as an initial white blood cell (WBC) count of !100 Â 10 9 /L, are at a high risk of early morbidity and mortality. 1 Early complications are attributed to leukostasis, a phenomenon associated with sludging of leukemic blasts in the microcirculation and adhesive interactions with capillary endothelium, especially affecting the brain and lung. 2 Intracranial hemorrhage and respiratory distress are the main causes of early mortality.
Leukapheresis is often applied for patients with hyperleukocytosis to rapidly decrease their WBC count. Some studies of adult patients have demonstrated that leukapheresis decreases early mortality but does not impact long-term outcome. Few studies have focused on the management of pediatric AML with hyperleukocytosis. Moreover, there is still no evidence that leukapheresis should be the standard procedure for the initial treatment of hyperleukocytosis. In pediatric patients, there are also disadvantages of applying leukapheresis. The placement of the large central venous catheter is more difficult to perform in pediatric patients and may cause bleeding or infections. Moreover, further thrombocytopenia and unstable blood pressure may occur during leukapheresis. Therefore, we performed a prospective, single-center, multiyear study to investigate the application of prompt chemotherapy, instead of leukapheresis, as the initial management for children with AML and hyperleukocytosis.
Materials and methods

Study design and patients
At Mackay Memorial Hospital (MMH), Taipei, Taiwan, there were 74 patients under the age of 18 years with de novo AML other than acute promyelocytic leukemia who were treated with two consecutive protocols, namely, MMH-AML-96 and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, from November 1, 1995, to May 31, 2012. 3, 4 Seventeen patients had an initial WBC count ! 100 Â 10 9 /L. One patient, who was deeply comatose due to severe multifocal cerebral hemorrhage at presentation and did not receive chemotherapy, was excluded from complete remission (CR) analysis.
Diagnosis
The diagnosis of AML and its subtypes was based on the FrencheAmericaneBritish (FAB) classification.
5e7 Immunophenotyping and cytogenetic studies were performed in all patients. Molecular genetic testing, including reverse transcriptase-polymerase chain reaction assays and Southern blot analysis, was performed in all patients as previously described. 8 In recent years, fluorescence in situ hybridization was applied in the detection of mixed lineage leukemia (MLL) gene rearrangement.
Treatment
At initial presentation, all patients immediately received intravenous fluid hydration. Rasburicase (recombinant urate oxidase) was used to treat hyperuricemia, if present. Instead of leukapheresis, prompt induction chemotherapy was given to all patients after a rapid initial diagnosis of AML by leukemic cell morphology, cytochemical stain, and/ or immunophenotyping. The regimens of induction chemotherapy in both the MMH-AML-96 and TPOG-AML-97A protocol were identically Ara-C (100 mg/m 2 /day Â 7) plus idarubicin (9 mg/m 2 /day Â 3). If CR was not achieved after one cycle of induction therapy, another one cycle of induction therapy with the same regimen was given. If CR could not be achieved after two cycles, second-line treatment including mitoxantrone (8 mg/m 2 /day Â 5) and etoposide (100 mg/m 2 /day Â 5) was given.
Initial outcomes
The CR was defined as less than 5% blasts in total nucleated cells in bone marrow aspirate with a regeneration of normal cell lines at the end of remission induction. Early complications and death were defined as events occurring before or during the first 2 weeks of chemotherapy. 9 Early complications were further classified into neurological symptoms, respiratory distress, bleeding events, renal insufficiency, and bacterial sepsis.
Statistical analysis
Comparisons of age, WBC count at diagnosis, and duration from admission to initiation of treatment of the AML patients with and without hyperleukocytosis were performed using the t test. Other characteristics of the patients based on univariate analysis were performed by the c 2 test. A p value < 0.05 was taken to be significant.
Results
The characteristics of the patients with or without hyperleukocytosis are summarized in Table 1 . The median age of the patients with hyperleukocytosis was 7.4 years (range: 0e16 years), and the median initial WBC count was 177 Â 10 9 /L (range: 117e635 Â 10 9 /L). The most frequent FAB subtypes were M4 and M5 (in 5 patients each), followed by M1 and M2 (in 3 patients each), and M0 (1 patient). Four patients had MLL gene rearrangements, one inv(16)/CBFb-MYH11, one monosomy 7, one trisomy 8, one complex karyotype, and nine normal karyotype. The abnormalities of the MLL gene included t(9;11)/MLL-AF9 in two patients, t(11;19)/MLL-ELL in one patient, and t(2;11)(q33;q23) in another patient. The median time between admission and initiation of chemotherapy was 4.5 hours (range: 2e72 hours) in the patients with hyperleukocytosis, and 13 hours (range: 2e120 hours) in the patients without hyperleukocytosis. The median WBC count at Day 14 was 1.0 Â 10 9 /L (range: 0.4e2.2 Â 10 9 /L) in the patients with hyperleukocytosis and 0.8 Â 10 9 /L (range: 0.2e1.8 Â 10 9 /L) in the patients without hyperleukocytosis. One patient with hyperleukocytosis and a stable clinical condition was hospitalized on a Friday afternoon and received induction chemotherapy 72 hours after admission.
The early complications in the patients with hyperleukocytosis are summarized in Table 2 . Seven patients (7/17, 41%) had one or more early complications before or during the first 2 weeks of induction chemotherapy, including four with neurological symptoms, three with respiratory distress, two with renal insufficiency, four with bleeding events, and four with bacterial sepsis. One patient, who had an initial WBC count of 475 Â 10 9 /L and received TPOG-AML-97A induction therapy within 24 hours after admission, died on the 7 th day from methicillinresistant coagulase-negative staphylococcal sepsis.
Fifteen of the 16 patients who received prompt chemotherapy achieved CR (93.8%). Ten patients achieved CR after one cycle of induction therapy, two patients after two cycles, and three patients after three cycles. The only patient with monosomy 7, who achieved CR after three cycles of induction /L and initial presentations of intracranial hemorrhage, retinal hemorrhage, and respiratory distress received intravenous hydration, platelet transfusion, and two doses of rasburicase (0.2 mg/kg/ dose) to reduce serum uric acid from 1370 mmol/L to 0 mmol/ L. Induction chemotherapy was initiated after 4 hours of hospitalization. The neurological and respiratory symptoms markedly improved in 1 week, and CR was achieved after one cycle of induction therapy. For the baby with congenital AML who had the highest initial WBC count (635 Â 10 9 /L), induction chemotherapy was initiated after 4 hours of hospitalization, and CR without early complications was achieved after two cycles of induction chemotherapy. The patients with hyperleukocytosis required more induction cycles than the patients without hyperleukocytosis to achieve CR. However, the CR rates were similar (93.8% vs. 98.2%; p Z 0.33).
Discussion
Hyperleukocytosis is a significant risk factor for early morbidity and mortality in adult and pediatric patients with AML. 10 Leukostasis is the main pathogenesis accounting for early complications and death. It was thought that with regard to leukostasis, a high leukocrit (fractional leukocyte volume) led to an increase in blood viscosity, which then caused an occlusion of microvessels. 11, 12 Accordingly, leukostasis is more frequent in AML than in acute lymphoblastic leukemia (ALL) because of the larger size of myeloblasts than lymphoblasts. However, most recent studies have demonstrated that interactions between leukemic blasts and vascular endothelial cells may be the key mechanism for leukostasis. Differences in adhesion molecules expressed on myeloblast and lymphoblast surfaces may account for the higher incidence of leukostasis in AML than in ALL. 2, 13 Inaba et al 9 compared two groups with AML and hyperleukocytosis (before and after the AML-83 protocol) and found that the incidence of early complications was similar, but that early mortality rate was lower in the late period group (2.8%) than in the early period group (22.9%). They concluded that early mortality in hyperleukocytic AML patients could be decreased with advanced supportive care and leukocytoreduction. Leukocytoreduction, which can be achieved by leukapheresis or prompt induction chemotherapy, is now considered to be the initial management choice for hyperleukocytic leukemia to prevent complications.
The advantages of leukapheresis are its rapid cytoreductive effect and modulation of the cell cycle in bone Ad Z admission; AML Z acute myeloid leukemia; C/T Z chemotherapy; CR Z complete remission; Dx Z diagnosis; ED Z early death; F Z female; FAB Z FrencheAmericaneBritish; H/D Z hemodialysis; ICH Z intracranial hemorrhage; LGI Z lower gastrointestinal tract; M Z male; MR-CONS Z methicillin-resistant coagulase-negative Staphylococci; P/D Z peritoneal dialysis; Pt Z patient; RD Z respiratory distress; RI Z renal insufficiency; TLS Z tumor lysis syndrome; WBC Z white blood cell. a Patient did not receive chemotherapy and was excluded from complete remission analysis.
marrow by increasing S-phase leukemic blasts, which can theoretically increase the efficacy of cell cycle-directed chemotherapeutic agents. 14e16 The main disadvantage of leukapheresis is the requirement of a large central venous catheter, which is not always immediately available for children and may increase the risk of infections. In addition, thrombocytopenia accompanied with WBC removal and a rebound in blast count after leukapheresis are also detrimental. 17 Further thrombocytopenia and infections may cause a delay in induction chemotherapy.
Although no randomized prospective studies regarding the efficacy of leukapheresis have been published, several retrospective studies have been reported. Thiébaut et al 14 reported that leukapheresis performed in AML patients with hyperleukocytosis (WBC count > 100 Â 10 9 /L) resulted in a low early mortality rate (2 of 53). Porcu et al 18 found that the early mortality (within 1 week) rate was 29.1%, and concluded that there was no correlation between the degree of leukocytoreduction by leukapheresis and early mortality. De Santis et al 19 reported that seven of the 15 patients who had leukostasis and underwent leukapheresis died within 1 week in spite of a significant reduction in WBC count.
Some retrospective studies have compared hyperleukocytic AML patients who were treated with or without leukapheresis. Giles et al 20 compared two groups who had a WBC count above 50 Â 10 9 /L and did (N Z 71) or did not (N Z 75) undergo leukapheresis. The results showed that leukapheresis reduced the 2-week mortality rate (p Z 0.006) but showed no significant improvement in CR and overall survival. Bug et al 21 compared two hyperleukocytic (WBC count > 100 Â 10 9 /L) AML patient groups who were treated with or without leukapheresis. The results showed a significantly lower risk of early death by Day 21 (p Z 0.015) with leukapheresis. Chang et al 22 compared two hyperleukocytic (WBC count > 100 Â 10 9 /L) AML patient groups with or without preinduction leukapheresis according to the decision by the physician. The results showed that leukapheresis did not significantly reduce early mortality (p Z 0.367) or the incidence of intracranial hemorrhage (p Z 0.349). However, they found that early chemotherapy within 48 hours after hospitalization significantly prevented early death (p Z 0.001).
Induction therapy is the mainstay of successful treatment for acute leukemia. For patients with hyperleukocytosis, induction chemotherapy not only rapidly reduces circulating WBC count, but also effectively destroys the leukemic blasts in bone marrow. Therefore, induction chemotherapy should be initiated as quickly as possible. In addition, prompt induction chemotherapy does not require an interventional procedure. Tumor lysis syndrome, which is the major concern after induction chemotherapy in patients with hyperleukocytosis, can be prevented by hydration, allopurinol, and rasburicase to reduce serum uric acid levels, 23 and correction of electrolyte imbalances or causes of reversible renal failure. 24 In our study, the median duration for the initiation of chemotherapy after admission was 4.5 hours. High CR and low early mortality rates were achieved. However, the high early complication rate (7/17) remains a challenge. Moreover, our patients with hyperleukocytosis required more induction cycles than the patients without hyperleukocytosis to achieve CR. Dutcher et al 25 also showed that hyperleukocytic AML patients had a lower CR rate. This may be related to high tumor burden or distinct entities of hyperleukocytic AML, which was associated with fms-like tyrosine kinase 3-internal tandem duplication. 26 However, the detailed pathophysiology is still uncertain. This was an observational study, and the leukapheresis comparison group was not included. Therefore, the data were analyzed in a univariate fashion. Furthermore, the number of patients included was small, and this limits the significance of the statistical power.
In conclusion, prompt chemotherapy treatment for children with AML and hyperleukocytosis can provide satisfactory initial treatment results without leukapheresis. Appropriate supportive care, including sufficient intravenous hydration, treatment of tumor lysis syndrome, correction of coagulopathy, and thrombocytopenia, should be initiated immediately. Most importantly, the induction chemotherapy should be started as soon as possible. Large randomized prospective studies are necessary to compare the initial outcomes of prompt chemotherapy alone versus leukapheresis in pediatric patients with AML and hyperleukocytosis.
